A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer

被引:11
作者
Manolakos, Peter [1 ]
Ward, Linda D. [1 ]
机构
[1] Clemson Univ, Healthcare Genet & Genom PhD Program, Clemson, SC 29634 USA
关键词
KRAS; mutations; STK11; co-mutation; KL; prognostic; predictive; NSCLC; non-small cell lung cancer; COOCCURRING GENOMIC ALTERATIONS; G12C MUTATION; CHECKPOINT INHIBITORS; TREATMENT OUTCOMES; PHASE-II; MUTANT; DOCETAXEL; SURVIVAL; THERAPY; 1ST-LINE;
D O I
10.3390/jpm13061010
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The Kirsten rat sarcoma viral oncogene homolog (KRAS) and serine/threonine kinase 11 (STK11) co-mutations are associated with the diverse phenotypic and heterogeneous oncogenic subtypes in non-small cell lung cancer (NSCLC). Due to extensive mixed evidence, there needs to be a review of the recent KRAS and STK11 mutation literature to better understand the potential clinical applications of these genomic biomarkers in the current treatment landscape. This critical review highlights the clinical studies that have elucidated the potential prognostic and predictive implications of KRAS mutations, STK11 mutations, or KRAS/STK11 co-mutations when treating metastatic NSCLC across various types of treatments (e.g., immune checkpoint inhibitors [ICIs]). Overall, KRAS mutations are associated with poor prognoses and have been determined to be a valid but weak prognostic biomarker among patients diagnosed with NSCLC. KRAS mutations in NSCLC have shown mixed results as a predictive clinical biomarker for immune checkpoint inhibitor treatment. Overall, the studies in this review demonstrate that STK11 mutations are prognostic and show mixed results as predictive biomarkers for ICI therapy. However, KRAS/STK11 co-mutations may predict primary resistance to ICI. Prospective KRAS/STK11-biomarker-driven randomized trials are needed to assess the predictive effect of various treatments on the outcomes for patients with metastatic NSCLC, as the majority of the published KRAS analyses are retrospective and hypothesis-generating in nature.
引用
收藏
页数:21
相关论文
共 77 条
[11]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[12]   Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy [J].
Bradbury, Penelope A. ;
Morris, Donald G. ;
Nicholas, Garth ;
Tu, Dongsheng ;
Tehfe, Moustapha ;
Goffin, John R. ;
Shepherd, Frances A. ;
Gregg, Richard W. ;
Rothenstein, Jeffrey ;
Lee, Christoper ;
Kuruvilla, Sara ;
Keith, Bruce D. ;
Torri, Vamsee ;
Blais, Normand ;
Hao, Desiree ;
Korpanty, Grzegorz J. ;
Goss, Glenwood ;
Melosky, Barbara L. ;
Mates, Mihaela ;
Leighl, Natasha ;
Ayoub, Jean-Pierre ;
Sederias, Joana ;
Feilotter, Harriet ;
Seymour, Lesley ;
Laurie, Scott A. .
LUNG CANCER, 2018, 120 :142-148
[13]   The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients [J].
Cai, Dongjing ;
Hu, Chengping ;
Li, Li ;
Deng, Shichao ;
Yang, Jing ;
Han Han-Zhang ;
Li, Min .
CANCER MEDICINE, 2020, 9 (01) :84-93
[14]   Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer [J].
Calles, Antonio ;
Liao, Xiaoyun ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Butaney, Mohit ;
Lydon, Christine ;
Dahlberg, Suzanne E. ;
Hodi, F. Stephen ;
Oxnard, Geoffrey R. ;
Jackman, David M. ;
Jaenne, Pasi A. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) :1726-1735
[15]  
Cho B.C., 2020, P AACR VIRT ANN M VI
[16]   Drugging the undruggable RAS: Mission Possible? [J].
Cox, Adrienne D. ;
Fesik, Stephen W. ;
Kimmelman, Alec C. ;
Luo, Ji ;
Der, Channing J. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (11) :828-851
[17]   Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer [J].
Cui, Wanyuan ;
Franchini, Fanny ;
Alexander, Marliese ;
Officer, Ann ;
Wong, Hui-Li ;
IJzerman, Maarten ;
Desai, Jayesh ;
Solomon, Benjamin J. .
LUNG CANCER, 2020, 146 :310-317
[18]   Somatic mutations affect key pathways in lung adenocarcinoma [J].
Ding, Li ;
Getz, Gad ;
Wheeler, David A. ;
Mardis, Elaine R. ;
McLellan, Michael D. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Greulich, Heidi ;
Muzny, Donna M. ;
Morgan, Margaret B. ;
Fulton, Lucinda ;
Fulton, Robert S. ;
Zhang, Qunyuan ;
Wendl, Michael C. ;
Lawrence, Michael S. ;
Larson, David E. ;
Chen, Ken ;
Dooling, David J. ;
Sabo, Aniko ;
Hawes, Alicia C. ;
Shen, Hua ;
Jhangiani, Shalini N. ;
Lewis, Lora R. ;
Hall, Otis ;
Zhu, Yiming ;
Mathew, Tittu ;
Ren, Yanru ;
Yao, Jiqiang ;
Scherer, Steven E. ;
Clerc, Kerstin ;
Metcalf, Ginger A. ;
Ng, Brian ;
Milosavljevic, Aleksandar ;
Gonzalez-Garay, Manuel L. ;
Osborne, John R. ;
Meyer, Rick ;
Shi, Xiaoqi ;
Tang, Yuzhu ;
Koboldt, Daniel C. ;
Lin, Ling ;
Abbott, Rachel ;
Miner, Tracie L. ;
Pohl, Craig ;
Fewell, Ginger ;
Haipek, Carrie ;
Schmidt, Heather ;
Dunford-Shore, Brian H. ;
Kraja, Aldi ;
Crosby, Seth D. ;
Sawyer, Christopher S. .
NATURE, 2008, 455 (7216) :1069-1075
[19]   Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers [J].
Dogan, Snjezana ;
Shen, Ronglai ;
Ang, Daphne C. ;
Johnson, Melissa L. ;
D'Angelo, Sandra P. ;
Paik, Paul K. ;
Brzostowski, Edyta B. ;
Riely, Gregory J. ;
Kris, Mark G. ;
Zakowski, Maureen F. ;
Ladanyi, Marc .
CLINICAL CANCER RESEARCH, 2012, 18 (22) :6169-6177
[20]   Non-Small Cell Lung Cancer, Version 3.2022 [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Aisner, Dara L. ;
Akerley, Wallace ;
Bauman, Jessica R. ;
Bharat, Ankit ;
Bruno, Debora S. ;
Chang, Joe Y. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
DeCamp, Malcolm ;
Dilling, Thomas J. ;
Dowell, Jonathan ;
Gettinger, Scott ;
Grotz, Travis E. ;
Gubens, Matthew A. ;
Hegde, Aparna ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Lin, Jules ;
Loo, Billy W. ;
Lovly, Christine M. ;
Maldonado, Fabien ;
Massarelli, Erminia ;
Morgensztern, Daniel ;
Ng, Thomas ;
Otterson, Gregory A. ;
Pacheco, Jose M. ;
Patel, Sandip P. ;
Riely, Gregory J. ;
Riess, Jonathan ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Singh, Aditi P. ;
Stevenson, James ;
Tam, Alda ;
Tanvetyanon, Tawee ;
Yanagawa, Jane ;
Yang, Stephen C. ;
Yau, Edwin ;
Gregory, Kristina ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (05) :497-530